

Chordate Medical presents interim report for Q3 2023 on Finwire TV

Chordate Medical Holding (publ) is releasing its interim report for Q3 2023 on Wednesday, November 1st, at 08:30. On the same day, at 10:00, the company invites you to a webcast presentation of the report with CEO Anders Weilandt on Finwire TV.

The presentation can be viewed through the following link: <https://www.finwire.tv/webcast/chordate-medical/q3-2023/>

Following the presentation, there will be a Q&A session where viewers can submit questions.

A recording of the presentation will be made available afterwards on the company's website www.chordate.com and on [Finwire TV's YouTube channel](#).

For more information, please contact:

Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate Medical presents interim report for Q3 2023 on Finwire TV](#)